| Literature DB >> 30401486 |
Mizuki Miura1, Shinichi Shirai2, Yukari Uemura3, Masaomi Hayashi2, Hiroshi Takiguchi2, Shinya Ito2, Mariko Yano2, Tomohiro Kawaguchi2, Takashi Morinaga2, Akihiro Isotani2, Shinichi Kakumoto4, Katsuhiro Seo4, Yoshio Arai5, Genichi Sakaguchi5, Kenji Ando2.
Abstract
Transcatheter aortic valve implantation (TAVI) often causes intraventricular conduction abnormalities (ICA), particularly left bundle branch block (LBBB) and advanced atrioventricular block, requiring pacemaker implantation (PMI). However, the relation between ICA and clinical outcomes after TAVI with balloon-expandable valves remains unclear, particularly in the Asian population. This retrospective study included all patients who underwent TAVI with balloon-expandable valves from October 2013 to September 2016. We defined ICA as new onset of complete LBBB (CLBBB) or PMI within 2 weeks after TAVI. We divided the patients into 2 groups: those with and without ICA (new-ICA and no-ICA groups) and we assessed 1-year outcome. Two hundred one consecutive patients underwent TAVI using balloon-expandable valves (mean age, 84.8 ± 5.7 years; women, 64%). ICA occurred in 47 patients (23%), 37 patients (18%) developed CLBBB, and 34 patients recovered from CLBBB within 1 year after TAVI. Ten patients (5%) who developed symptomatic bradycardia required PMI within 2 weeks after TAVI. At 30 days after PMI, 7 patients already had a very low ventricular pacing rate, and 6 patients who recovered from bradycardia needed pacing at 1 year. Patients with ICA tended to have high 1-year all-cause mortality, but there was no significant difference between the 2 groups (12% vs 7%, p = 0.15). In conclusion, ICA occurred in 23% of patients after TAVI with balloon-expandable valves, and approximately 90% of them recovered from ICA during the follow-up. There was no significant difference in 1-year all-cause mortality between the new-ICA and no-ICA groups.Entities:
Mesh:
Year: 2018 PMID: 30401486 DOI: 10.1016/j.amjcard.2018.10.005
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778